Abstract: An enzyme detection device (1) for detecting the presence, in a sample, of an enzyme capable of modifying a provided substrate (10). The device (1) comprises a substrate which has a modification region (14) that is sensitive to modification by the enzyme from an unmodified state to a modified state. The device (1) further comprises a substrate recognition molecule (16) which binds the modification region (14) in either the modified or the unmodified state. The modification region 14 of the substrate is preferentially bound by the substrate recognition molecule (16) as compared with the enzyme when mixed. The device further comprises a detectable label (18) coupled to the substrate recognition molecule (17).
Abstract: A method for diagnosing, or differentially diagnosing, interstitial cystitis (IC) involves detecting or measuring increased expression of a biomarker Endothelin 1 (ET-1) in a biological sample from a mammalian subject, particularly in the urine or urothelial tissue. An increased level of expression of ET-1 above the level of expression in the same sample of a healthy mammalian subject is an indication of a diagnosis of IC. Such diagnosis may further involve identify other clinical symptoms of IC. Additionally the method may use additional biomarkers, such as Hb-EFG, EGF, APF, IL-8, IL-6, and cGMP. Assay methods and diagnostic reagents and kits for such diagnosis are provided. Methods and compositions for treating IC by reducing the action, production or synthesis of ET-1 in the urine or urothelium and/or inhibiting its binding to its ETA and/or ETB receptors are also provided.
Type:
Grant
Filed:
September 23, 2010
Date of Patent:
October 22, 2013
Assignee:
The Trustees of the University of Pennsylvania
Abstract: Disclosed are a method for early, sensitively and reliably detecting and distinguishing intrahepatic cholangiocarcinoma in a malignant tumor occurring primarily in the liver in a simple way, and a kit thereof. In the method, a glycan biomarker consisting of a lectin WFA (Wisteria floribunda Agglutinin)-binding glycoprotein derived from intrahepatic cholangiocarcinoma is used as a cancer marker to detect intrahepatic cholangiocarcinoma by detecting the cancer marker in a test specimen. The method for detecting intrahepatic cholangiocarcinoma can clearly differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma and enables early detection and determination with a performance clinically acceptable in terms of applicability, sensitivity and precision.
Type:
Grant
Filed:
February 23, 2010
Date of Patent:
October 15, 2013
Assignees:
National Institute of Advanced Industrial Science and Technology, University of Tsukuba
Abstract: Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich ?-2-glycoprotein (LRG); S100-A8 (calgranulin); ?-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-?-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and ?-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals.
Type:
Grant
Filed:
December 30, 2009
Date of Patent:
September 17, 2013
Assignee:
Children's Medical Center Corporation
Inventors:
Alex Kentsis, Hanno Steen, Richard Bachur
Abstract: The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided.
Type:
Grant
Filed:
September 21, 2011
Date of Patent:
August 27, 2013
Assignee:
Nestec S.A.
Inventors:
Nicholas Chi-Kwan Ling, Shui Long Wang, Dunrui Wang, Sharat Singh
Abstract: This method and device detects past use of drugs of abuse when the drug substance and its metabolites are no longer present in the body, based on the detection of the antibodies formed in response to said drug, and persist even after this drug and its metabolites are cleared from the body. False positive rate is reduced by screening out subjects with heightened inflammatory state. One embodiment of the invention sets forth the method and device comprising: testing a set of samples for levels of an inflammation biomarker; determining a subset of samples with inflammation biomarker level below a first predetermined threshold; testing samples within the subset of samples for a presence of drug-specific antibodies, for a pre-specified set of drugs; determining which samples within the subset have drug-specific antibody level exceeding pre-specified threshold; and providing an output indicating the samples within the subset having the drug-specific antibodies.
Type:
Grant
Filed:
April 20, 2012
Date of Patent:
August 6, 2013
Inventors:
Marina Aleksandrova Myagkova, Michael Ezrokhi, Arkady Gershteyn
Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.
Type:
Grant
Filed:
June 7, 2012
Date of Patent:
July 16, 2013
Assignees:
Sysmex Corporation, Kagoshima University
Abstract: A method for determining the amount of NT-proBNP in blood samples from felines. The method includes detecting degradation products of feline NT-proBNP by various methods, including using antibodies, kits and devices.
Type:
Grant
Filed:
May 31, 2012
Date of Patent:
July 9, 2013
Assignee:
IDEXX Laboratories, Inc.
Inventors:
Mahalakshmi Yerramilli, Michael Atkinson, Murthy V. S. N. Yerramilli
Abstract: The present invention relates to a method for detecting an antigen with use of an antibody and an enzyme. Specifically, the present invention provides a method for detecting an antigen without use of a labeled-antibody. the method comprises immersing particles in a first buffer solution which is predicted to contain the antigen; wherein an antibody and a multi-copper oxidase CueO are immobilized on each surface of the particles, and the antibody reacts specifically with the antigen. The method further comprises the following steps recovering the obtained particles; mixing the particles recovered, an oxidation-reduction indicator (reductant), and a second buffer solution so as to prepare a reaction solution; measuring an activity degree of the multi-copper oxidase CueO contained in the reaction solution; determining that the first buffer solution contains the antigen based on the above activity degree.
Abstract: Developed is an adiponectin-recognition material which is inexpensive and excellent in: productivity; stability of quality and a structure; and convenience. The present invention provides a peptide consisting of not more than 50 amino acids and having bindability with adiponectin.
Type:
Grant
Filed:
April 26, 2011
Date of Patent:
May 21, 2013
Assignee:
Sharp Kabushiki Kaisha
Inventors:
Mao Yamada, Ai Tsutsui, Yoshiro Akagi, Naoya Ichimura, Atsushi Mizusawa, Takakiyo Tada